Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Launched by AFFILIATED HOSPITAL OF QINGHAI UNIVERSITY · Aug 25, 2017

Keywords

ClinConnect Summary

To assess the Efficiency and safety of Paclitaxel + S-1 + Oxaliplatin(PSOX) in the Patients with Locally Advanced or Advanced Gastric Cancer

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
• • 2. Locally advanced, or recurrent, or metastasis disease；
• • 3. Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed;
• • 4. Life expectancy of at least 3 months;
• • 5. ECOG score 0-1;
• • 6. Age: 18\~70 years old;
• • 7. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). For example: WBC\>4.0×109/L, NEU \>1.5×109/L, PLT\>100×109/L, BIL\<1.5 times of upper limit of normal reference value, ALT and AST\<2.5 times of upper limit of normal reference value, and CRE\<1.2mg/dl;
• • 8. Good cardiac function before the recruitment, no seizure of myocardial infarction in past half year, and controllable hypertension and other coronary heart diseases;
• • 9. Not concomitant with other uncontrollable benign diseases before the recruitment (e.g. the infection in the lung, kidney and liver);
• • 10. Not participating in other study projects before and during the treatment;
• • 11. Voluntarily signed the informed consent.
• Exclusion Criteria:
• • 1. Previously treated with first-line chemotherapy;
• • 2. Allergy to the drugs in this protocol;
• • 3. Pregnant or lactating women;
• • 4. Women at childbearing age and of pregnancy desire during the study.